Top

Gepubliceerd in:

2012 | OriginalPaper | Hoofdstuk

19. Healed Myocardial Infarction

Auteurs : Gary S. Francis, MD, Daniel J. Garry, MD, PhD

Uitgeverij: Springer US

Abstract

Among the many devastating complications of healed myocardial infarction is heart failure (HF). Despite its ubiquitous role in causing death and disability around the globe, HF is quite difficult to define. It has a great deal of heterogeneity, can be acute or chronic, may involve primarily the left ventricle or right ventricle (or both), can be associated with a low or normal left ventricular ejection fraction (LVEF), and has numerous causes. This chapter focuses on HF due to chronic coronary artery disease (CAD).

Virtually any form of heart disease can lead to heart failure. In general, HF is a clinical syndrome caused by structural and/or functional changes in the heart that lead to dyspnea, fatigue, and in many cases, salt and water retention. Comorbidities such as CAD, hypertension, diabetes mellitus, chronic kidney disease, or atrial fibrillation frequently accompany HF, and may contribute to or aggravate the HF syndrome.

In the end, patients typically become gradually more and more disabled and eventually die prematurely from pump dysfunction or arrhythmia. Improvement in therapy the past 30 years has improved survival, but HF continues to exact a toll on patients, their families, and the worldwide economy.

vorige hoofdstuk Complications of Acute Myocardial Infarction

volgende hoofdstuk Nonatherosclerotic Ischemic Heart Disease

Felker GM, Shaw LK, O’Conner CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210–8.PubMedCrossRef

Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–8.PubMedCrossRef

Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 1987;59:634–8.PubMedCrossRef

Farb A, Tang AL, Burke AP, et al. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92:1701–9.PubMedCrossRef

Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28:1781–8.PubMedCrossRef

Tavazzi L. Towards a more precise definition of heart failure aetiology. Eur J Cardiol. 2002;22:192–5.CrossRef

Kannel WB, Ho K, Thom K. Changing epidemiological features of cardiac failure. Eur Heart J. 1994;72(Suppl):S3–9.

Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.PubMedCrossRef

Fox C, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus. The Framingham heart study. Circulation. 2007;115:1544–50.PubMedCrossRef

10.

Braunwald E, Rutherford J. Reversible ischemic left ventricular dysfunction: evidence of the “hibernating myocardium”. J Am Coll Cardiol. 1986;8:1467–70.PubMedCrossRef

11.

Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Eur Heart J. 2004;25:815–36.PubMedCrossRef

12.

Gheoghiade M, Sopko G, DeLuca L, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202–13.CrossRef

13.

Cohn J, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.PubMedCrossRef

14.

Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril or both after myocardial infarction. Circulation. 2005;111:3411–9.PubMedCrossRef

15.

Cheong BYC, Muthupillai R, Wilson JM, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging. Survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120:2069–76.PubMedCrossRef

16.

Uretsky BF, Thygesen K, Armstrong P, et al. Acute coronary findings at autopsy in heart failure patients with sudden death. Results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611–6.PubMedCrossRef

17.

Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease. Early assessment and treatment. J Am Coll Cardiol. 2009;53:254–63.PubMedCrossRef

18.

Goldberg RJ, Ciampa J, Lessard D, et al. Long-term survival after heart failure: a contemporary population based perspective. Arch Intern Med. 2007;167:490–6.PubMedCrossRef

19.

Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: Part 1. Diagnosis, prognosis, and measurement of diastolic function. Circulation. 2002;105:1387–93.PubMedCrossRef

20.

Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail. 2007;13:569–76.PubMedCrossRef

21.

Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:221–8.PubMedCrossRef

22.

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777–81.PubMedCrossRef

23.

Cleland JG, Tendera M, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.PubMedCrossRef

24.

Cleland JGF, Daubert J-C, Erdmann E, et al., on behalf of the CARE-CHF Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

25.

Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.PubMedCrossRef

26.

Epstein AE, DiMarco JP, Ellebogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol. 2008;51:e1–62.PubMedCrossRef

27.

Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438–45.PubMedCrossRef

28.

St. John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–90.PubMedCrossRef

29.

Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response. A report from the CARE-CHF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol. 2008;52:438–45.PubMedCrossRef

30.

Marwick TH. Hype and hope in the use of echocardiography for selection for cardiac resynchronization therapy. The Tower of Babel revisited. Circulation. 2008;117:2573–6.PubMedCrossRef

31.

Moss AJ, Hall WJ, Cannom DS, et al., for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.

32.

Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daybert C, on behalf of the REVERSE Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Coll Cardiol. 2008;52:1834–43.

33.

St. John Sutton M, Ghio S, Plappert T, et al., on behalf of the REVERSE Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858–65.

34.

Francis GS, Tang WHW. Early cardiac resynchronization therapy and reverse remodeling in patients with mild heart failure. Is it time? Circulation. 2009;120:1845–6.PubMedCrossRef

35.

Daubert C, Gold MR, Abraham WT, et al., on behalf of the REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol. 2009;54:1837–46.

36.

Stratton JR, Nemanich JW, Johannessem K-A, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1998;78:1388–93.CrossRef

37.

Freudenberger RS, Hellkamp AS, Halpern JL, et al., for the SCD-HeFT Investigators. Risk of thromboembolism in heart failure. An analysis from Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2008;115:2637–41.

38.

Massie B, Cillins JF, Ammon SE, et al., for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616–24.

39.

Vargas SO, Sampson BA, Schoen FJ. Pathological detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. Mod Pathol. 1999;12:635–45.PubMed

40.

Abildstrom SZ, Ottesen MM, Rask-Madsen C, et al. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol. 2005;104:184–9.PubMedCrossRef

41.

Verma S, Mesana TG. Mitral valve repair for mitral-valve prolapse. N Engl J Med. 2009;361:2261–9.PubMedCrossRef

42.

Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–72.PubMedCrossRef

43.

Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875–83.PubMedCrossRef

Titel: Healed Myocardial Infarction
Auteurs: Gary S. Francis, MD
Daniel J. Garry, MD, PhD
Uitgeverij: Springer US
Boek: Coronary Heart Disease
Print ISBN: 978-1-4614-1474-2

Elektronisch ISBN: 978-1-4614-1475-9

Copyright: 2012
DOI: https://doi.org/10.1007/978-1-4614-1475-9_19

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen